Category Archives: TB

TAG’s TB drug guide aims to equip activists

By on .

While the impact of tuberculosis grew over the last decades of the 20th century, with drug resistant forms of the disease and HIV fueling its spread and slowing cures, the drugs used to treat TB have not changed. Bedaquiline and delaminid are the only new TB drugs to have been approved in over forty years, […]

TB drug approvals, distribution deal inches options forward, but MDR TB treatment access still uncertain where needed most

By on .

Last week’s developments in TB treatment included the announcement that bedaquiline, the currently most promising medicine for multi-drug-resistant tuberculosis, will become available to patients in 130 low- and middle-income countries through the Stop TB Partnership’s Global Drug Facility. That good news for multidrug-resistant TB patients, many of whom have run out of other options, was […]

TB treatment advocates to Sanofi pharmaceutical company on drug price: “We cry enough!”

By on .

A little more than four months ago, a collection of organizations and individuals concerned with the high price of rifapentine, a drug that could treat tuberculosis more quickly than other drugs, and also treat TB infection before it caused illness, wrote to Sanofi, the company that makes the medicine. Noting that government funding that had […]

Long road to effective TB treatment hits speed bumps: Regulatory refusal of one TB drug candidate, stalled progress on another

By on .

Momentum toward gathering an effective arsenal of treatment for tuberculosis may have gathered speed in recent years, the 2013 Pipeline Report jointly released by the Treatment Action Group and HIV i-base in June pointed out, yet it falls far short of what people sick and infected with TB worldwide need now. Case in point, the […]

CDC report on U.S. TB drug shortage reflects local and global challenges

By on .

With no medicine on hand, a father and his infant who have just been diagnosed with multidrug-resistant tuberculosis go untreated, the delay prolonging their recoveries as well as the time they will remain infectious. The delay adds to the risk that they will get sicker and resistant to more drugs, increases the odds that those […]

FDA panel finds new type of TB drug effective, raising hopes for treatment of drug-resistant strains

By on .

Dr. Dalene von Delft had a choice between dying  or going deaf, and that was a choice only if the arduous treatment she was undergoing for drug-resistant tuberculosis worked. The South African pediatrician had contracted a resistant strain of the disease caring for patients, and the only potentially effective treatment was showing one of its […]

Global Fund TB allocation shows need for work, action, groups say

By on .

When the Global Fund Board released its September meeting “decision points” document on funding allocation methods, it was, watchers noted, a part of a piece of a work in progress. But one decision will hold for the next year, and will impact efforts to roll out advances in tuberculosis diagnosis and treatment — the decision […]

Drug maker seeks approval for use against multidrug-resistant tuberculosis

By on .

Makers of an investigational tuberculosis drug that has been urged for “compassionate use” approval in South Africa have applied to the European Medicines Agency to market the medicine as part of a combination therapy for multidrug-resistant tuberculosis. “If approved, bedaquiline could be one of the first drugs with a new mechanism of action for tuberculosis […]